SUNNYVALE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the "Company" or "23andMe"), announced today the completion of the previously announced 1-for-20 reverse stock split of the Company's Class A and Class B common stock and confirmed that such reverse stock split became effective as of 12:01 a.m. EST on October 16, 2024 (the "Effective Time"). The Company effected the reverse stock split by filing an amendment to the Company's Certificate of Incorporation with the Secretary ...

SUNNYVALE, Calif., Oct. 11, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (the "Company" or "23andMe"), announced today that the 1-for-20 reverse stock split of the Company's Class A and Class B common stock will become effective as of 12:01 a.m. EST on October 16, 2024 (the "Effective Time"). As previously disclosed, at the Company's 2024 Annual Meeting of Stockholders, the Company's stockholders voted to approve an amendment to the Company's Certificate of Incorporation (the "Charter Amendment ...

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating 23andMe Holding Co. regarding potential breaches of fiduciary duties by the board of directors and CEO Anne Wojcicki in relation to her efforts to acquire all outstanding shares of the company that she does not already own [1][3]. Investigation Details - On July 29, 2024, CEO Wojcicki made a non-binding proposal to acquire all shares of 23andMe not owned by her or her affiliates [2]. - The board's Special Committee rejected this offer on August 2, 2024, citing lack of premium, absence of committed financing, and conditional nature of the proposal [3]. Board Resignation - On September 17, 2024, all independent directors of 23andMe resigned, expressing concerns over the lack of a fully financed and actionable proposal from Wojcicki [3]. - The independent directors indicated a strategic disagreement with Wojcicki and emphasized the need to prioritize shareholder interests [3]. Legal Implications - BFA is concerned that the actions of the board and Wojcicki may constitute breaches of fiduciary duties, particularly regarding the company's value and potential self-interested dealings [3]. - The firm aims to protect the interests of 23andMe shareholders and hold fiduciaries accountable for any breaches [3].

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating 23andMe Holding Co. regarding potential breaches of fiduciary duties by the board of directors and CEO Anne Wojcicki in connection with her efforts to acquire all outstanding shares of the company that she does not already own [1][3]. Investigation Details - On July 29, 2024, CEO Wojcicki made a non-binding proposal to acquire all shares of 23andMe not already owned by her or her affiliates [2]. - The Special Committee of the Board rejected this offer on August 2, 2024, citing lack of premium, absence of committed financing, and conditional nature of the proposal [3]. Board Resignation - On September 17, 2024, all independent directors of 23andMe resigned, expressing concerns over the lack of a fully financed and actionable proposal from Wojcicki that would benefit non-affiliated shareholders [3]. - The independent directors indicated a strategic disagreement with Wojcicki and highlighted her concentrated voting power as a reason for their resignation [3]. Legal Concerns - BFA is concerned that the actions of the board and Wojcicki may constitute breaches of fiduciary duties, particularly regarding the prioritization of company value and potential self-interested dealings [3]. - The firm intends to take necessary actions to protect the interests of 23andMe shareholders and hold fiduciaries accountable for any breaches [3]. Shareholder Actions - Current holders of 23andMe stock are encouraged to submit their information to BFA for potential legal options, with representation on a contingency fee basis [4]. - Shareholders will not be responsible for court costs or litigation expenses, as BFA will seek court approval for any fees [4]. Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, having achieved significant recoveries in past cases [5].

This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility: 23andMe CEO Anne Wojcicki speaks at an announcement for the Breakthrough Prize in Life Sciences at Genentech Hall on UCSF's Mission Bay campus in San Francisco, Feb. 20 2013. Credit: AP Photo/Jeff Chiu, File All of 23andMe's independent directors resigned from its board this week, a rare move that marks the latest challenge for t ...

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating claims on behalf of investors in 23andMe Holding Co. (NASDAQ: ME) concerning the offer to acquire 23andMe by its controlling shareholder, Anne Wojcicki, who is 23andMe's co-founder and CEO. Under the terms of the proposed deal, 23andMe shareholders would receive $0.40 per share in cash. After the market closed on July 31, 2024, Ms. Wojcicki, who holds approximately 49% of 23andMe's voting power, made an offer to acquire the remain ...

NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into 23andMe Holding Co. (NASDAQ:ME) regarding whether the board of directors and the co-founder and current CEO Anne Wojcicki ("Wojcicki") of 23andMe breached their fiduciary duties in connection with Wojcicki's ongoing effort to purchase all 23andMe shares she does not already own. If you are a holder of 23andMe, you are encouraged to submit your information at: https://www.bfalaw ...

Board Resignations and CEO's Response - Seven out of eight board members of 23andMe have resigned, leaving the CEO as the sole remaining member [1] - The resigning directors cited dissatisfaction with the CEO's buyout offer, stating it was not in the best interest of non-affiliated shareholders [2] - The CEO expressed surprise and disappointment at the resignations, maintaining that taking the company private remains the best strategic option [3] Buyout Proposal and Rejection - The CEO proposed to acquire all outstanding shares not owned by her or her affiliates at $0.40 per share in July [4] - A special committee rejected the proposal, deeming it insufficient and not in the best interest of non-affiliated shareholders [5] - The directors noted no significant progress over the past five months, leading them to believe no satisfactory proposal is forthcoming [6] Financial and Market Performance - 23andMe's share price dropped to a new low of $0.30 following the board resignations, rebounding slightly to $0.35 the next day [7] - The company is now valued at less than its cash reserves and is being referred to as a penny stock by financial publications [7] - Since going public in 2021, 23andMe has never turned a profit and risks depleting its cash reserves by next year [8] Operational Challenges - 23andMe is best known for its saliva-based genetic ancestry test kits [8] - The company has faced significant challenges, including a data breach that compromised the personal information of nearly 7 million users [8]

All seven members of 23andMe's board resigned in a stinging rebuke to a proposal by CEO Anne Wojcicki's plans to to take the company private. Wojcicki, who has been trying to take the company private since April, proposed to acquire all outstanding shares of 23andMe not owned by her or her affiliates for $0.40 per share, in July. "I am surprised and disappointed by the decision of the directors to resign," Wojcicki said in a memo Tuesday to employees obtained by The Post. 3 All seven members of 23andMe's bo ...

Anne Wojcicki, co-founder and chief executive officer of 23andme Inc., during the South by Southwest (SXSW) festival in Austin, Texas, US, on Friday, March 10, 2023. All seven independent directors of 23andMe resigned from the company's board Tuesday, a move that CEO Anne Wojcicki said left her "surprised and disappointed," according to a memo to employees. Wojcicki, who co-founded 23andMe in 2006, said she remains committed to taking the company private. The genetic-testing company went public in 2021 thro ...